Impact on ALL protocol
CSVT has impacted treatment in almost all patients who developed this complication. This affected patient by delaying or deleting subsequent doses and thus compromising maximal benefit from treatment. In the majority of patients with CSVT, there was omission of few ASP doses, whereas the vast majority had to miss or delay doses of ASP until CSVT stabilized on anticoagulant therapy. Steroids were as well missed or delayed because of such complication. ASP was omitted from the whole treatment in one patient who had a life-threatening superior sagittal sinus thrombosis that was complicated by a large intracranial hemorrhage (ICH) and required two craniotomies.